Sponsored by:

Tumor > Neotect

Scott Williams
Apr 2, 2002

Neotect (Tc99-m-Depreotide) (P-829)

Clinical

Chemistry and pharmacology

Patient Instructions

Imaging Protocol

Interpretation

Indications for the exam

Dosimetry

Complications/Side Effects

HAMA Formation (Immunogenicity)



Latest in Nuclear Medicine
TrueBeam radiotherapy system
Varian nets FDA clearance for TrueBeam in osteoarthritis treatment
March 19, 2026
Inside imaging innovation at ECR 2026
Sponsored
Inside imaging innovation at ECR 2026
March 3, 2026
Radiation Symbols Adobe Mia
JAMA study shows wide global variation in cardiac imaging radiation dose
February 25, 2026
Dna Blue
Genetic mutations linked to poor outcomes in Pluvicto patients
February 23, 2026
Related Stories
Whole Body
Nuclear Medicine
Prostascint (111In-Capromab Pendetide) (CYT-356)
Primary Ct
Nuclear Medicine
PET > PET tumor imaging > Breast Cancer
Lsegs
Nuclear Medicine
Pulmonary
Inside imaging innovation at ECR 2026
Sponsor Content
Inside imaging innovation at ECR 2026
More in Nuclear Medicine
Varian nets FDA clearance for TrueBeam in osteoarthritis treatment
By AuntMinnie.com staff writers
Varian has received U.S. FDA clearance for the use of low-dose radiation therapy with its Varian TrueBeam radiotherapy systems.
March 19, 2026
TrueBeam radiotherapy system
TerraPower Isotopes to build Ac-225 facility in Philadelphia
By AuntMinnie.com staff writers
The new site will increase the company's actinium-225 (Ac-225) production capacity 20-fold.
March 18, 2026
Isotopes1
JAMA study shows wide global variation in cardiac imaging radiation dose
By Kate Madden Yee
"Radiation doses varied significantly between imaging tests and among patients receiving the same tests," researchers reported.
February 25, 2026
Radiation Symbols Adobe Mia
Genetic mutations linked to poor outcomes in Pluvicto patients
By Will Morton
TP53, PTEN, and RB1 mutations may serve as prognostic biomarkers.
February 23, 2026
Dna Blue
The rise of theranostics: Part 7 -- Nuclear medicine technologists' rapid evolution
By Liz Carey
As theranostics gains speed, nuclear medicine technologists (NMTs) face a defining moment.
February 19, 2026
Image 3 Simulation Lab Courtesy Of Uab Feb 2026
Starget and CMIT collaborate
By AuntMinnie.com staff writers
The strategic collaboration aims to develop peptide radioligand therapies for cancer.
February 18, 2026
A Ipartnership
NorthStar inks Ac-225 supply deal with Bioemtech
By AuntMinnie.com staff writers
Initial deliveries will begin in the first quarter of 2026.
February 18, 2026
Isotopes1
Journal of Nuclear Medicine names new editor in chief
By AuntMinnie.com staff writers
Herrmann is currently chair of nuclear medicine at the University of Duisburg-Essen in Germany.
February 11, 2026
Herrman Ken Thumbnail
Niowave inks Ac-225 supply deal with Novartis
By AuntMinnie.com staff writers
The agreement will provide Novartis with a supply of the medical isotope to support its growing portfolio of radioligand therapies.
February 11, 2026
Isotopes1
Nucs AI establishes medical advisory board
By AuntMinnie.com staff writers
Nucs AI has formed its medical advisory board to ensure the company's AI theranostics tech is aligned with clinical practice.
January 29, 2026
Ai Abstract Researcher (1)
New study seeks to tailor RLT to individual patients
By Will Morton
A new clinical trial aims to determine how doctors can optimize targeted radioligand therapy (RLT) for men with prostate cancer.
January 26, 2026
Prostate
Georgia ProtonCare Center enters asset purchase agreement with Emory
By AuntMinnie.com staff writers
Georgia ProtonCare Center has entered into an asset purchase agreement with Emory University.
January 22, 2026
Business Development Graph Up 400
Page 1 of 441
Next Page